BioViva

BioViva is a biotechnology company that focuses on the development of new gene therapies to slow the aging process. The company was founded by Elizabeth Parrish in 2015, who also serves as the CEO. BioViva uses a combination of telomerase gene therapy and myostatin inhibitor to combat aging.

History

BioViva was founded in 2015 by Elizabeth Parrish, who has a background in advocacy for the use of genetic engineering to combat aging. The company's approach is based on the work of George M. Church, a geneticist at Harvard Medical School.

In 2015, Parrish announced that she had undergone BioViva's experimental therapies to combat aging. This made her the first person to be treated with gene therapy to extend telomere length.

Research and Development

BioViva's research and development efforts are focused on gene therapies that can slow the aging process. The company's main therapies are based on the activation of the telomerase gene and the inhibition of myostatin.

The telomerase gene therapy is designed to extend the length of telomeres, the protective caps on the ends of chromosomes. Shortening of telomeres is associated with aging and a higher risk of age-related diseases.

The myostatin inhibitor is designed to increase muscle mass and strength, which often decrease with age. Inhibition of myostatin has been shown to increase muscle mass in mice and humans.

Controversies

BioViva has been the subject of controversy due to its unconventional approach to research and development. The company has been criticized for testing its therapies on its CEO, Elizabeth Parrish, before conducting clinical trials.

See Also

• Gene therapy
• Telomere
• Myostatin
• Aging

• 
  BioViva logo